Abstract
Introduction: The East Asia S-1 Trial in Lung Cancer (EAST-LC) was a randomized phase III study conducted in East Asia that demonstrated the non-inferiority of S-1 to docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). Here, we reported the results of the Japanese subgroup treated with docetaxel 60 mg/m 2 , the standard dosage in Japan. Patients and methods: Patients were randomized 1:1 to receive either S-1 or docetaxel. The primary endpoint was overall survival (OS); the secondary endpoints included progression-free survival (PFS), response rate (RR), quality of life (QOL), and safety. Results: Patient characteristics in the Japanese subgroup (n = 724) were similar to those in the overall EAST-LC population. Median OS was 13.4 months in the S-1 group and 12.6 months in the docetaxel group. In pemetrexed-pretreated patients, OS with S-1 was similar to that with docetaxel. Median PFS was 2.9 and 3.0 months in the S-1 and docetaxel groups, respectively. RR was 9.4% and 10.3% in the S-1 and docetaxel groups, respectively. The QOL of patients treated with S-1 was better compared with that of patients treated with docetaxel. Decreased appetite and diarrhea were more common in the S-1 group, whereas the frequency of neutropenia and febrile neutropenia was markedly higher in the docetaxel group. Conclusions: This Japanese subgroup analysis showed that S-1 had similar efficacy to docetaxel in patients with previously treated advanced NSCLC. These results are similar to those of the overall EAST-LC population.
| Original language | English |
|---|---|
| Pages (from-to) | 485-493 |
| Number of pages | 9 |
| Journal | International Journal of Clinical Oncology |
| Volume | 24 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - May 15 2019 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Surgery
- Hematology
- Oncology
Cite this
Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment : EAST-LC. / Sugawara, Shunichi; Nakagawa, Kazuhiko; Yamamoto, Nobuyuki; Nokihara, Hiroshi; Ohe, Yuichiro; Nishio, Makoto; Takahashi, Toshiaki; Goto, Koichi; Maemondo, Makoto; Ichinose, Yukito; Seto, Takashi; Sakai, Hiroshi; Gemma, Akihiko; Imamura, Fumio; Shingyoji, Masato; Saka, Hideo; Inoue, Akira; Takeda, Koji; Okamoto, Isamu; Kiura, Katsuyuki; Morita, Satoshi; Tamura, Tomohide.
In: International Journal of Clinical Oncology, Vol. 24, No. 5, 15.05.2019, p. 485-493.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment
T2 - EAST-LC
AU - Sugawara, Shunichi
AU - Nakagawa, Kazuhiko
AU - Yamamoto, Nobuyuki
AU - Nokihara, Hiroshi
AU - Ohe, Yuichiro
AU - Nishio, Makoto
AU - Takahashi, Toshiaki
AU - Goto, Koichi
AU - Maemondo, Makoto
AU - Ichinose, Yukito
AU - Seto, Takashi
AU - Sakai, Hiroshi
AU - Gemma, Akihiko
AU - Imamura, Fumio
AU - Shingyoji, Masato
AU - Saka, Hideo
AU - Inoue, Akira
AU - Takeda, Koji
AU - Okamoto, Isamu
AU - Kiura, Katsuyuki
AU - Morita, Satoshi
AU - Tamura, Tomohide
PY - 2019/5/15
Y1 - 2019/5/15
N2 - Introduction: The East Asia S-1 Trial in Lung Cancer (EAST-LC) was a randomized phase III study conducted in East Asia that demonstrated the non-inferiority of S-1 to docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). Here, we reported the results of the Japanese subgroup treated with docetaxel 60 mg/m 2 , the standard dosage in Japan. Patients and methods: Patients were randomized 1:1 to receive either S-1 or docetaxel. The primary endpoint was overall survival (OS); the secondary endpoints included progression-free survival (PFS), response rate (RR), quality of life (QOL), and safety. Results: Patient characteristics in the Japanese subgroup (n = 724) were similar to those in the overall EAST-LC population. Median OS was 13.4 months in the S-1 group and 12.6 months in the docetaxel group. In pemetrexed-pretreated patients, OS with S-1 was similar to that with docetaxel. Median PFS was 2.9 and 3.0 months in the S-1 and docetaxel groups, respectively. RR was 9.4% and 10.3% in the S-1 and docetaxel groups, respectively. The QOL of patients treated with S-1 was better compared with that of patients treated with docetaxel. Decreased appetite and diarrhea were more common in the S-1 group, whereas the frequency of neutropenia and febrile neutropenia was markedly higher in the docetaxel group. Conclusions: This Japanese subgroup analysis showed that S-1 had similar efficacy to docetaxel in patients with previously treated advanced NSCLC. These results are similar to those of the overall EAST-LC population.
AB - Introduction: The East Asia S-1 Trial in Lung Cancer (EAST-LC) was a randomized phase III study conducted in East Asia that demonstrated the non-inferiority of S-1 to docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). Here, we reported the results of the Japanese subgroup treated with docetaxel 60 mg/m 2 , the standard dosage in Japan. Patients and methods: Patients were randomized 1:1 to receive either S-1 or docetaxel. The primary endpoint was overall survival (OS); the secondary endpoints included progression-free survival (PFS), response rate (RR), quality of life (QOL), and safety. Results: Patient characteristics in the Japanese subgroup (n = 724) were similar to those in the overall EAST-LC population. Median OS was 13.4 months in the S-1 group and 12.6 months in the docetaxel group. In pemetrexed-pretreated patients, OS with S-1 was similar to that with docetaxel. Median PFS was 2.9 and 3.0 months in the S-1 and docetaxel groups, respectively. RR was 9.4% and 10.3% in the S-1 and docetaxel groups, respectively. The QOL of patients treated with S-1 was better compared with that of patients treated with docetaxel. Decreased appetite and diarrhea were more common in the S-1 group, whereas the frequency of neutropenia and febrile neutropenia was markedly higher in the docetaxel group. Conclusions: This Japanese subgroup analysis showed that S-1 had similar efficacy to docetaxel in patients with previously treated advanced NSCLC. These results are similar to those of the overall EAST-LC population.
UR - http://www.scopus.com/inward/record.url?scp=85062699644&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062699644&partnerID=8YFLogxK
U2 - 10.1007/s10147-019-01396-z
DO - 10.1007/s10147-019-01396-z
M3 - Article
VL - 24
SP - 485
EP - 493
JO - International Journal of Clinical Oncology
JF - International Journal of Clinical Oncology
SN - 1341-9625
IS - 5
ER -